Mdm2-SNP309 polymorphism in prostate cancer: No evidence for association with increased risk or histopathological tumour characteristics

British Journal of Cancer

Volumn 99, Issue 1, 2008, Pages 78-82

  Stoehr, R ^a   Hitzenbichler, F ^b   Kneitz, B ^c   Hammerschmied, C G ^a   Burger, M ^b   Tannapfel, A ^d   Hartmann, A ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Mdm2 SNP309; p53 pathway; Prostate cancer; RFLP

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL CYCLE REGULATION; CELL SURVIVAL; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UBIQUITINATION;

AGED; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 46349108445     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604441     Document Type: Article

References (28)

1. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110
2. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602
3. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315
4. Deniaud E, Baguet J, Mathieu AL, Pages G, Marvel J, Leverrier Y (2006) Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 25: 7096-7105
5. Dong JT (2006) Prevalent mutations in prostate cancer. J Cell Biochem 97: 433-447
6. Dumur CI, Dechsukhum C, Ware JE, Cofiled SS, Best AM, Wilkinson DS, Garrett CT, Ferreira-Gonzalez A (2003) Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 81: 260-269
7. Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M, Jakobkiewicz-Banecka J, Kobierska-Gulida G, Szymanowska A, Skokowski J, Roessner A, Schneider-Stock R (2004) MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer 43: 285-295
8. Epstein JI, Algaba F, Allsbrook WC, Bastacky S, Boccon-Gibod L, De Marzo AM, Egevad L, Furusato M, Hamper UM, Helpap B, Humphrey PA, Iczkowski KA, Lopez-Beltran A, Montironi R, Rubin MA, Sakr WA, Samaratunga H, Parkin DM (2004) Tumours of the prostate. In Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs, Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) World Health Organization, classification of tumours. pp 159-216. IARC, Lyon
9. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
10. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F (2008) EAU guidelines for prostate cancer. Eur Urol 53: 68-80
11. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H (2007) MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16: 2717-2723
12. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J (1994) Alterations in the p53 and MDM-2 gene are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 145: 287-293
13. Khor LY, Desilvio M, Al-Saleem T, Hammond ME, Grignon DJ, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A (2005) MDM2 as a predictor of prostate carcinoma outcome: an analysis of radiation therapy oncology group protocol8610. Cancer 104: 962-967
14. Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I, Camara-Lopes LH (2001) Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 14: 428-436
15. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
16. Lindström S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Bälter KA, Brookes AJ, Sun J, Chang BL, Liu W, Li G, Isaacs WB, Adolfsson J, Grönberg H, Xu J (2006) Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 66: 1729-1743
17. Muthusamy V, Hobbs C, Nolgueira C, Cordon-Cardo C, McKee PH, Chin L, Bosenberg MW (2006) Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45: 447-454
18. Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N (2004) Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas. Int J Cancer 109: 363-369
19. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C (1999) Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5: 2082-2088
20. Phan D, Cheng CJ, Galfione M, Vakar-Lopez F, Tunstead J, Thompson NE, Burgess RR, Najjar SM, Yu-Lee LY, Lin SHL (2004) Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res 64: 3072-3078
21. Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448
22. Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, Cordon-Cardo C (2007) A polymorphism in HDM2 (SNP309) associated with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 13: 3215-3220
23. Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B (1999) Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 39: 79-86
24. Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumors. Wiley & Sons, New York
25. Sotomaa K, Liyanarachchi S, Mecklin JP, Järvinen H, Aaltonen LA, Peltimäki P, de la Chapelle A (2005) p53 codon 72 and Mdm2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 11: 6840-6844
26. Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31
27. Wilkening S, Bermejo JL, Hemminki K (2007) MDM2 SNP 309 and cancer risk: a combined analysis. Carcinogenesis 28: 2262-2267
28. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Höfler H, Bauchinger M, Werner M (2001) Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 84: 202-208